User:Indefensible/Draft/Beam Therapeutics
 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
| Company type | Public company |
|---|---|
| Nasdaq: BEAM | |
| ISIN | US07373V1052 |
| Industry | Biotechnology |
| Founded | 2017 |
| Founder | Feng Zhang, David R. Liu, J. Keith Joung, and John Evans |
| Headquarters | Cambridge, United States |
| Website | www |
Beam Therapeutics is an American biotechnology company based in Cambridge, Massachusetts in the fields of gene therapy and genome editing using CRISPR and prime editing technologies, whereby DNA sequences can be modified even more precisely compared to previous methods.[1][2]
History[edit]
Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[3] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors.[4] In a February 2020 IPO, the company raised $180 million.[5] The first clinical trials for therapies are expected in 2021.[6]
See also[edit]
References[edit]
- ^ "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ.
{{cite web}}: CS1 maint: url-status (link) - ^ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.
- ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.
- ^ Sewell, Dawson; Burns, Joe; Villarisco, Julius John; Faraguna, Carla; Ogolla, Henry; Gomila, Jude; Scherfner, Erin; Hammond, Rebecca; Solanki, Bhupendra. "Beam Therapeutics". Golden. Retrieved 2021-07-08.
{{cite web}}: CS1 maint: url-status (link) - ^ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.
- ^ Philippidis, Alex (2020-02-06). "Beam Therapeutics, Base Editing Drug Developer, Raises $180M in IPO". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-07-08.
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |
Category:American companies established in 2017 Category:Biotechnology companies of the United States Category:Gene therapy Category:Health care companies based in Massachusetts Category:Life sciences industry Category:Pharmaceutical companies established in 2017 Category:Pharmaceutical companies of the United States